Significant decreases in FDG-PET scans, MAPK and PI3K/AKT signaling cascades and stable disease were achieved in 46% of patients, with little toxicity (dizziness, and dry mouth) suggesting that single agent riluzole is unlikely to have a long-lasting benefit in melanoma patients [71]. The gene discussed is AKT1; the disease is melanoma.